Literature DB >> 26826311

Hepatitis C virus infection from the perspective of heterologous immunity.

Markus Cornberg1, Heiner Wedemeyer2.   

Abstract

Heterologous immunity can impact the natural course of subsequent infections by different mechanisms such as polarization of TH1/TH2 responses, induction of cytokines and T cell cross-reactivity. In the case of hepatitis C virus (HCV) infection, heterologous immunity helps to explain the high variability in clinical outcomes. This review discusses how other infections can alter the natural course of hepatitis C and how HCV infection influence unrelated infections.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26826311     DOI: 10.1016/j.coviro.2016.01.005

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  12 in total

1.  Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion.

Authors:  Levi B Watkin; Rabinarayan Mishra; Anna Gil; Nuray Aslan; Dario Ghersi; Katherine Luzuriaga; Liisa K Selin
Journal:  J Allergy Clin Immunol       Date:  2017-06-16       Impact factor: 10.793

Review 2.  Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.

Authors:  L B Dustin; B Bartolini; M R Capobianchi; M Pistello
Journal:  Clin Microbiol Infect       Date:  2016-08-31       Impact factor: 8.067

3.  T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes.

Authors:  Amalie K Bentzen; Lina Such; Kamilla K Jensen; Andrea M Marquard; Leon E Jessen; Natalie J Miller; Candice D Church; Rikke Lyngaa; David M Koelle; Jürgen C Becker; Carsten Linnemann; Ton N M Schumacher; Paolo Marcatili; Paul Nghiem; Morten Nielsen; Sine R Hadrup
Journal:  Nat Biotechnol       Date:  2018-11-19       Impact factor: 68.164

Review 4.  Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension.

Authors:  Babita Agrawal; Shakti Singh; Nancy Gupta; Wen Li; Satish Vedi; Rakesh Kumar
Journal:  Int J Mol Sci       Date:  2017-07-27       Impact factor: 5.923

5.  Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.

Authors:  Dinler A Antunes; Maurício M Rigo; Martiela V Freitas; Marcus F A Mendes; Marialva Sinigaglia; Gregory Lizée; Lydia E Kavraki; Liisa K Selin; Markus Cornberg; Gustavo F Vieira
Journal:  Front Immunol       Date:  2017-10-04       Impact factor: 7.561

6.  Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires.

Authors:  Nuray Aslan; Levi B Watkin; Anna Gil; Rabinarayan Mishra; Fransenio G Clark; Raymond M Welsh; Dario Ghersi; Katherine Luzuriaga; Liisa K Selin
Journal:  mBio       Date:  2017-12-05       Impact factor: 7.867

7.  Clearance of a persistent picornavirus infection is associated with enhanced pro-apoptotic and cellular immune responses.

Authors:  Carolina Stenfeldt; Michael Eschbaumer; George R Smoliga; Luis L Rodriguez; James Zhu; Jonathan Arzt
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

8.  Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens.

Authors:  Babita Agrawal; Nancy Gupta; Satish Vedi; Shakti Singh; Wen Li; Saurabh Garg; Jie Li; Rakesh Kumar
Journal:  Cells       Date:  2019-05-26       Impact factor: 6.600

9.  Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity.

Authors:  Benedikt Strunz; Julia Hengst; Katja Deterding; Michael P Manns; Markus Cornberg; Hans-Gustaf Ljunggren; Heiner Wedemeyer; Niklas K Björkström
Journal:  Nat Commun       Date:  2018-06-11       Impact factor: 14.919

Review 10.  Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections.

Authors:  Babita Agrawal
Journal:  Front Immunol       Date:  2019-11-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.